Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.

By Michael G. Silverman, B. Ference, K. Im, S. Wiviott, R. Giugliano, S. Grundy, E. Braunwald, M. Sabatine. Journal of the American Medical Association (JAMA), 2016

1,332 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Immunology, Surgery

View Paper: https://www.semanticscholar.org/paper/ffe2bc97855c4dac59e664dc2c1f67d0e4ea3250

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Immunology

In Surgery

Citations in the corpus

2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019, background): “Particular consideration was given to results from metaanalyses confirming the dose-dependent reduction in ASCVD with LDL-C-lowering agents; the greater the absolute LDL-C reduction, the greater the CV risk reduction.(35,36,50,115) The benefits related to LDL-C reduction are not specific for statin ”
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel (2017, result): “Indeed, in a recent meta-analysis of 49 studies including 312 175 participants and 39 645 major vascular events that compared the effects of 9 different types of lipid-lowering therapies, nearly all of these therapeutic approaches to lowering LDL-C were associated with a consistent 20–25% proportion”
Pleiotropic Effects of Statins on the Cardiovascular System (2017, background): “statins and fall on the Cholesterol Treatment Trialists regression line.(55,56) Nonstatin trials often take longer to show a benefit then”
Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis (2020, background): “Multiple large-scale randomised trials of lipid-modifying therapies have conclusively shown that lowering of cholesterol in atherogenic lipoproteins leads to a reduction in risk of CHD [4,5].”
The MR-Base platform supports systematic causal inference across the human phenome (2018, result): “…for violations of IV assumptions, results remained compatible with a causal effect of higher LDL cholesterol on CHD in sensitivity analyses and were similar to findings from clinical trials ( Silverman et al., 2016 ; White et al., 2016 ) and observational studies ( Di Angelantonio et al., 2009 ).”